Evidence map›Paper›PMID 38089695›Full record

ArticleEpilepsy & behavior reports2023

Societal costs and quality of life analysis in patients undergoing resective epilepsy surgery: A one-year follow-up.

L Maas, J Kellenaers, G van Mastrigt, S M J van Kuijk, M C G Vlooswijk, M Hiligsmann, S Klinkenberg, L Wagner, J Nelissen, O E M G Schijns and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epilepsy & behavior reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

L MaasDepartment of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands.
J KellenaersDepartment of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands.
G van MastrigtDepartment of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, The Netherlands.
S M J van KuijkDepartment of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, The Netherlands.
M C G VlooswijkDepartment of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands.
M HiligsmannDepartment of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, The Netherlands.
S KlinkenbergDepartment of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, The Netherlands.
L WagnerSchool for Mental Health & Neuroscience, University Maastricht, Maastricht, The Netherlands.
J NelissenDepartment of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands.
O E M G SchijnsDepartment of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands.
H J M MajoieSchool for Mental Health & Neuroscience, University Maastricht, Maastricht, The Netherlands.
K RijkersDepartment of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands.
Maastricht University · NLUniversity Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although effectiveness of Resective Epilepsy Surgery (RES) for patients with drug-resistant epilepsy (DRE) is widely proven, research on the impact of societal costs (SC) is lacking. The aim of this study is to provide both clinical and economic outcomes of RES by offering an overview of treatment effectiveness as well as SC of RES in a cohort of 30 Dutch DRE patients. This project serves as a pilot project to offer an up-to-date model for larger cost-effectiveness studies. Medical consumption, productivity losses, disease-specific and generic health-related quality of life (QoL), and seizure frequency were assessed before and 3-, 6-, and 12-months post-surgery with validated questionnaires. Linear mixed models, ANOVAs, and logistic regressions were performed. SC for the first year after RES entailed €54,376 and decreased over time. Moreover, 50% of patients experienced a clinically important increase in disease-specific QoL and 53% of patients in generic health-related QoL. Lastly, 73% of patients reached seizure freedom 12 months postoperative. Seizure reduction was correlated with increase in disease-specific QoL. Within one year after surgery, RES leads to reduction in SC and improvements in QoL over time. Future research should encompass longer follow-up periods, larger sample size, and a cost-effectiveness analysis with a comparator.

Indexed as

Cost-effectivenessDrug-resistant epilepsy patientsEpilepsyQuality of lifeResective epilepsy surgerySocietal costs

Identifiers

PMID38089695
PMCPMC10711171
OpenAlexW4388807181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.